About SUPPRELIN® LA -
Designed for Control

SUPPRELIN LA is the first and only 12-month implant to treat central precocious puberty1

The once-yearly implant offers you the confidence to:

  • Minimize the potential for interruptions in suppression of FSH and luteinizing hormone (LH), with continuous therapy for 12 months1,2
  • Start and stop the delivery of medication with a minor surgical procedure1
  • Schedule monitoring appointments around your, and your patients', schedules
  • Help your patients receive continuous therapy for an entire year1

Subcutaneous implant provides continuous release of a GnRH agonist

 

In a clinical trial, SUPPRELIN LA maintained LH suppression with no escapes for 12 months2

References:
1. SUPPRELIN® LA [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Solutions Inc; 2011.
2. Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab. 2007;92(5):1697-1704.

Next: SUPPRELIN® LA LH Suppression

Indication

SUPPRELIN® LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP).

Important Safety Information

  • SUPPRELIN LA is contraindicated in women who are or may become pregnant, and in patients who are hypersensitive to GnRH or GnRH agonist analogs. Safety and effectiveness in pediatric patients under the age of 2 years has not been established.

  • SUPPRELIN LA, like other GnRH agonists, initially causes a transient increase in serum concentrations of estradiol in females and testosterone in both sexes during the first week of treatment, with worsening or onset of new symptoms during this period. Within 4 weeks of therapy, gonadal steroid suppression occurs and manifestations of puberty decrease.

  • Implant insertion and removal is a surgical procedure and should utilize aseptic technique. Careful adherence to the recommended insertion and removal procedures is recommended. On occasion, localizing and/or removal of implant products have been difficult and imaging techniques were used, including ultrasound, CT, or MRI (this implant is not radiopaque).

  • Rare events of spontaneous extrusion have been observed in clinical trials.

  • LH, FSH and estradiol or testosterone should be monitored at 1 month post implantation then every 6 months. Every 6-12 months, height and bone age should also be assessed.

  • In clinical trials, the most common adverse reactions involved the implant site and included bruising, pain, soreness, erythema and swelling.

Please see the accompanying full Prescribing Information.